Osimertinib (Tagrisso) and the EGFR Lung Cancer Landscape

Osimertinib, sold as Tagrisso, is a third-generation EGFR tyrosine kinase inhibitor and a reference point for targeted therapy in non-small cell lung cancer (NSCLC). Few drugs have been developed so deliberately across the whole disease course.

Mechanism at a glance

Osimertinib is an oral, irreversible EGFR inhibitor taken once daily. It targets exon 19 deletions and L858R mutations as well as T790M, and it spares wild-type EGFR to a greater extent than earlier inhibitors. Common adverse effects include rash, diarrhea and, rarely, interstitial lung disease and cardiac effects.

Where it came from

It was designed to inhibit EGFR-sensitizing mutations and the T790M resistance mutation, and it penetrates the central nervous system, which matters because brain metastases are common in this population. Over time it moved from later lines into first-line treatment (FLAURA), the adjuvant setting after resection (ADAURA), and after chemoradiation in unresectable stage III disease (LAURA).

The competitive set

• Osimertinib plus chemotherapy (FLAURA2) pushes the incumbent’s own regimen forward, and the final overall survival analysis was statistically significant.
• Amivantamab plus lazertinib, a bispecific antibody and a third-generation TKI, challenges first-line positioning; in MARIPOSA it showed an overall survival advantage over osimertinib, with more serious adverse events.
• Other EGFR TKIs and next-generation inhibitors aim at resistance and uncommon mutations.
• Antibody-drug conjugates are moving in: Datroway received accelerated FDA approval in June 2025 for EGFR-mutated NSCLC after an EGFR TKI and platinum chemotherapy, and others are in late-stage trials.

Intelligence questions worth asking

1. How do survival data, tolerability and administration burden compare across first-line options?
2. What resistance mechanisms emerge, and are later-line therapies matched to them?
3. How aggressively are physicians testing for EGFR and for other drivers at diagnosis?
4. How will early-stage use change the later-line market?

Targeted therapy in lung cancer is a good example of why treatment algorithm maps need regular updating.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Sep 14, 2026: At WCLC 2026, a post hoc exploratory eight-year analysis of ADAURA (adjuvant osimertinib) showed overall survival of 79% vs 64% in stage IB-IIIA disease (HR 0.52). (OncLive)
• Sep 1, 2026: JAMA published a Phase 3 in 294 patients with EGFR and TP53 co-mutated NSCLC: osimertinib plus pemetrexed/carboplatin vs osimertinib alone gave median PFS of 34 vs 15.6 months (HR 0.44). Overall survival was only about 31% mature, and grade 3 or higher adverse events were 62.4% vs 14.9%. (ASCO Post)
• Dec 17, 2025: FDA approved Rybrevant Faspro, a subcutaneous amivantamab, for all indications of IV amivantamab, including with lazertinib. (FDA)
• Sep 7, 2025: FLAURA2 final overall survival was presented at WCLC 2025: HR 0.77, median OS 47.5 vs 37.6 months for osimertinib plus chemotherapy vs osimertinib alone. AstraZeneca had announced the result on July 21. (ecancer)
• Jun 23, 2025: FDA granted accelerated approval to Datroway for EGFR-mutated NSCLC after an EGFR-targeted therapy and platinum chemotherapy (response rate 45%, median duration of response 6.5 months). (CURE)
• 2025: MARIPOSA final overall survival, with J&J’s amivantamab plus lazertinib vs osimertinib: HR 0.75, three-year OS 60% vs 51%. Grade 3 or higher adverse events were 80% vs 52%. (ASCO Post)
• Sep 26, 2024: FDA approved osimertinib for unresectable stage III EGFR-mutated NSCLC after chemoradiation (LAURA): median PFS 39.1 vs 5.6 months (company-reported). (AstraZeneca)

Upcoming catalysts

• Oct 23-27, 2026: ESMO Congress, Madrid. OncoDaily lists several EGFR late-breaking abstracts, including SAFFRON (osimertinib plus savolitinib) and SANOVO (first-line EGFR/MET dual inhibition).
• Ongoing: TROPION-Lung14 and TROPION-Lung15 (Datroway with or around osimertinib); no readout dates have been announced.

Bottom line

Osimertinib shows how a targeted drug can own a biomarker-defined population from late-line to early-stage disease. Rivals now have to prove benefit on top of a very strong baseline, which raises the evidence bar for every new entrant.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.